Harbour Capital Advisors LLC Acquires Shares of 13,650 BioLife Solutions, Inc. (NASDAQ:BLFS)

Harbour Capital Advisors LLC bought a new position in BioLife Solutions, Inc. (NASDAQ:BLFS) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 13,650 shares of the medical equipment provider’s stock, valued at approximately $361,000.

Several other large investors have also recently modified their holdings of the stock. Mutual of America Capital Management LLC bought a new position in BioLife Solutions during the second quarter valued at $8,592,000. Rockefeller Capital Management L.P. boosted its stake in shares of BioLife Solutions by 81.3% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 585,497 shares of the medical equipment provider’s stock worth $14,661,000 after purchasing an additional 262,504 shares during the period. State Street Corp grew its holdings in BioLife Solutions by 7.3% during the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock valued at $35,364,000 after purchasing an additional 95,788 shares during the last quarter. Envestnet Asset Management Inc. raised its position in BioLife Solutions by 261.5% in the 2nd quarter. Envestnet Asset Management Inc. now owns 127,215 shares of the medical equipment provider’s stock worth $2,726,000 after purchasing an additional 92,021 shares during the period. Finally, Fred Alger Management LLC boosted its position in shares of BioLife Solutions by 6.0% during the second quarter. Fred Alger Management LLC now owns 1,579,138 shares of the medical equipment provider’s stock valued at $33,841,000 after buying an additional 88,840 shares during the period. Institutional investors own 93.24% of the company’s stock.

Insider Transactions at BioLife Solutions

In other BioLife Solutions news, CFO Troy Wichterman sold 987 shares of the business’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $27.02, for a total value of $26,668.74. Following the completion of the transaction, the chief financial officer now directly owns 121,779 shares in the company, valued at approximately $3,290,468.58. The trade was a 0.80 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Aby J. Mathew sold 25,000 shares of the firm’s stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $21.17, for a total transaction of $529,250.00. Following the completion of the sale, the executive vice president now owns 302,046 shares in the company, valued at $6,394,313.82. This represents a 7.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 103,129 shares of company stock valued at $2,344,018. Corporate insiders own 2.20% of the company’s stock.

BioLife Solutions Stock Performance

Shares of NASDAQ:BLFS opened at $26.97 on Tuesday. The firm has a 50 day moving average of $26.04 and a 200 day moving average of $24.37. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $1.25 billion, a price-to-earnings ratio of -25.44 and a beta of 1.92. BioLife Solutions, Inc. has a 52 week low of $14.50 and a 52 week high of $28.88.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. TD Cowen boosted their price objective on BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Benchmark restated a “buy” rating and issued a $30.00 price target on shares of BioLife Solutions in a report on Thursday, December 19th. Craig Hallum lifted their price objective on shares of BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. HC Wainwright dropped their target price on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. Finally, Northland Securities raised their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $29.43.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.